Gefitinib

  (geh-FIH-tih-nib)

This page contains brief information about gefitinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s):		Iressa
FDA Approved:		Yes

FDA Approval for Gefitinib

Gefitinib is approved to treat:

• Non-small cell lung cancer that is locally advanced or has metastasized (spread to other parts of the body). It is used in patients whose disease has not gotten better with other chemotherapy.

Gefitinib is available only as part of a special program called the Iressa Access Program. It is also being studied in the treatment of other types of cancer.

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Gefitinib - A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Targeted Cancer Therapies - Information about the use of this drug to treat cancer.

Clinical Trial Results: Gefitinib Improves Progression-free Survival for Metastatic Lung Cancers with EGFR Mutations - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Trial of Gefitinib for Advanced Lung Cancer Closes Early - Information from the NCI Press Office about this drug.

Find Clinical Trials for Gefitinib - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Back to Top